# Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study

> **NCT05555329** · PHASE4 · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 12 (actual)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma
- Multiple Myeloma, Refractory

## Interventions

- **DRUG:** Pomalidomide 4 mg every day in cycle 1
- **DRUG:** Pomalidomide 4 mg every other day in cycle 2
- **DRUG:** Pomalidomide 2 mg every day in cycle 2
- **DRUG:** Pomalidomide 2 mg every day in cycle 3
- **DRUG:** Pomalidomide 4 mg every other day in cycle 3

## Key facts

- **NCT ID:** NCT05555329
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2024-02-14
- **Final completion:** 2024-02-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05555329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05555329, "Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05555329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*